[1]
|
Turkington TG. Introduction to PET instrumentation[J], J Nucl Med Technol, 2001, 29(1):4-11. |
[2]
|
Varagnolo L, Stokkel MPM, Mazzi U, et al. 18F-labelled radiopharmaceuticals for PET in oncology, excluding FDG[J]. Nucl Med Biol, 2000, 27:103-112. |
[3]
|
Wang MF, Tang GH, Gao X,et al. Clinical experimental study of fluorine-18 sodium fluoride as a skeletal imaging a-gent[J]. Asian J Nucl Med, 2001, 1(3):142-146. |
[4]
|
Cook GJ, Lodge MA, Blake GM, et al. Differences in skeletal kinetics between vertebral and humeral bone measured by 18F-fluoride positron emission tomography in postmenopausal women[J]. J Bone Miner Res, 2000, 15(4):763-769. |
[5]
|
Shiue CY, Fowler JS, Wolf AP, et al. No-carrier added fluorine-18 labeled N-methylspiroperidol:Synthesis and biodistribution in mice[J]. J Nucl Med, 1986, 27:226-234. |
[6]
|
王明芳.放射性示踪剂在脑功能PET中的应用[J].国外医学·放射医学核医学分册,2001,25(6):246-249.
|
[7]
|
Saha GB, Maclntyre WJ and Go RT. Cyclotrons and positron emission tomography radiopharmaceutical for clinical imaging[J]. Semin Nucl Med, 1992, 22(3):150-161. |
[8]
|
Mankoff DA, Peterson LM, Tewson TJ, et al.[18F] Fluo-roestradiol radiation dosimetry in human PET studies[J]. J Nucl Med, 2001, 42(4):679-684. |
[9]
|
Bading TB, Alauddin MM, Fissekis TD, et al. Blocking catabolism with eniluracil enhances PET studies of 5-[18F] fluorouracil pharmacokinetics[J]. J Nucl Med, 2000, 41(10):1714-1724. |
[10]
|
Stauss AD, Stauss LG, Hohenberger PSP, et al. Fluorine-18-fluorouracil to predict therapy response in liver metas-tases from colorectal carcinoma[J]. J Nucl Med, 1998, 39(7):1197-1202. |
[11]
|
Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F] fluoroethyl)-L-tyrosine for tumor imaging[J]. J Nucl Med, 1999, 40(1):205-212. |
[12]
|
Hara T, Kosaka N and Kishi H. Development of 18F-fluo-roethylcholine for cancer imaging with PET:Synthesis, biochemistry, and prostate cancer imaging[J]. J Nucl Med, 2002,43(2):187-199. |
[13]
|
Lehtio K, Oikonen V, Gronroos T, et al. Imaging of blood flow and hypoxia in head and neck cancer:Initial evaluation with [15O]H2O and [18F]fluoroerythronitromidazole PET[J]. J Nucl Med, 2001,42(11):1643-1652. |
[14]
|
Gronroos T, Eskola O, Lehtio K, et al. Pharmacokinetics of [18F]FETNIM:A potential hypoxia marker for PET[J]. J Nucl Med, 2001, 42(9):1397-1404. |
[15]
|
Alauddin MM, Shahinan A, Gordon EM, et al. Preclinical evaluation of the penciclovir analog 9-(4-[18F]fluoro-3-hy-droxymethylbutyl)guanine for in vivo measurement of suicide gene expression with PET[J]. J Nucl Med, 2001, 42(11):1682-1690. |
[16]
|
Hustinx R, Eck SL and Alavi A. Potential applications of PET imaging developing novel cancer therapies[J]. J Nucl Med, 1999,40(6):995-1002. |
[17]
|
Lyer M, Barrio JR, Namavari M, et al. 8-[18F] Fluoropenci-clovir:an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET[J]. J Nucl Med, 2001,42(1):96-105. |
[18]
|
Passchier J, Waarde A, Pieterman RM, et al. In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF[J]. J Nucl Med, 2000, 41(11):1830-1835. |
[19]
|
Passchier J, Waarde A, Vaalburg W, et al. On the quantification of [18F]MPPF binding to 5-HT1A receptors in the human brain[J]. J Nucl Med, 2001,42(7):1025-1031. |